Multi-site, multi-country evaluation of analytical and operational performance of a low-mid volume chemiluminescent immunoassay analyzer

M. H. De Keijzer, S. Perkins, V. Motta, D. Morelli, J. P. Cristol, A. M. Dupuy, Y. Hong, S. Watanabe, C. Waerdt, R. W. Grunewald

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: A new automated immunoassay low-mid volume (≤ 250 immunoassays/day) chemiluminescent analyzer, Abbott Architect i1000 SR, was evaluated by seven laboratories around the world (4 in Europe, one each in Canada, Japan, and the U.S.A.) to demonstrate equivalent performance for key operating characteristics (e.g., precision, turn around time, limit of detection, functional sensitivity, and linearity). Methods: The laboratories followed standard protocols to assess precision, limit of detection (LoD), functional sensitivity, assay linearity, method comparison, and sample carryover. Turn around time for three stat assays (B-hCG, BNP, and CK-MB) and the time required to complete workloads of 50 and 100 tests with a mixture of 75% routine tests and 25% stat tests was also evaluated. Results: Total precision was typically <5% CV for nine immunoassays. Analytical performance met design goals and demonstrated equivalency to package insert data for assays on market and in use for an existing high volume immunoassay system. Stat turn around times were consistent with the fixed analytical time of 15.6 minutes and met the expectations of the laboratories. Measured test throughput ranged from 47 - 54 tests per hour and demonstrated that the analyzer was fit for the intended purpose of supporting a laboratory that performs ≤ 250 immunoassays per day. Conclusions: A multisite, international analyzer familiarization study is a practical means of confirming that a new instrument meets both a manufacturer's design specifications and users' real world expectations and provides a pragmatic test for the system. The experience of investigators at seven sites around the world indicates that a new fully automated chemiluminescent system is suitable for use.

Original languageEnglish
Pages (from-to)363-370
Number of pages8
JournalClinical Laboratory
Volume55
Issue number9-10
Publication statusPublished - 2009

Fingerprint

Immunoassay
Turnaround time
Assays
Limit of Detection
Product Labeling
Workload
Throughput
Canada
Specifications
Japan
Research Personnel

Keywords

  • Chemiluminescent immunoassay
  • Immunoassay
  • Immunoassay analyzer
  • Instrument evaluation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

De Keijzer, M. H., Perkins, S., Motta, V., Morelli, D., Cristol, J. P., Dupuy, A. M., ... Grunewald, R. W. (2009). Multi-site, multi-country evaluation of analytical and operational performance of a low-mid volume chemiluminescent immunoassay analyzer. Clinical Laboratory, 55(9-10), 363-370.

Multi-site, multi-country evaluation of analytical and operational performance of a low-mid volume chemiluminescent immunoassay analyzer. / De Keijzer, M. H.; Perkins, S.; Motta, V.; Morelli, D.; Cristol, J. P.; Dupuy, A. M.; Hong, Y.; Watanabe, S.; Waerdt, C.; Grunewald, R. W.

In: Clinical Laboratory, Vol. 55, No. 9-10, 2009, p. 363-370.

Research output: Contribution to journalArticle

De Keijzer, MH, Perkins, S, Motta, V, Morelli, D, Cristol, JP, Dupuy, AM, Hong, Y, Watanabe, S, Waerdt, C & Grunewald, RW 2009, 'Multi-site, multi-country evaluation of analytical and operational performance of a low-mid volume chemiluminescent immunoassay analyzer', Clinical Laboratory, vol. 55, no. 9-10, pp. 363-370.
De Keijzer, M. H. ; Perkins, S. ; Motta, V. ; Morelli, D. ; Cristol, J. P. ; Dupuy, A. M. ; Hong, Y. ; Watanabe, S. ; Waerdt, C. ; Grunewald, R. W. / Multi-site, multi-country evaluation of analytical and operational performance of a low-mid volume chemiluminescent immunoassay analyzer. In: Clinical Laboratory. 2009 ; Vol. 55, No. 9-10. pp. 363-370.
@article{fb4aae897c3e4cbcb4e5e576d01def73,
title = "Multi-site, multi-country evaluation of analytical and operational performance of a low-mid volume chemiluminescent immunoassay analyzer",
abstract = "Background: A new automated immunoassay low-mid volume (≤ 250 immunoassays/day) chemiluminescent analyzer, Abbott Architect i1000 SR, was evaluated by seven laboratories around the world (4 in Europe, one each in Canada, Japan, and the U.S.A.) to demonstrate equivalent performance for key operating characteristics (e.g., precision, turn around time, limit of detection, functional sensitivity, and linearity). Methods: The laboratories followed standard protocols to assess precision, limit of detection (LoD), functional sensitivity, assay linearity, method comparison, and sample carryover. Turn around time for three stat assays (B-hCG, BNP, and CK-MB) and the time required to complete workloads of 50 and 100 tests with a mixture of 75{\%} routine tests and 25{\%} stat tests was also evaluated. Results: Total precision was typically <5{\%} CV for nine immunoassays. Analytical performance met design goals and demonstrated equivalency to package insert data for assays on market and in use for an existing high volume immunoassay system. Stat turn around times were consistent with the fixed analytical time of 15.6 minutes and met the expectations of the laboratories. Measured test throughput ranged from 47 - 54 tests per hour and demonstrated that the analyzer was fit for the intended purpose of supporting a laboratory that performs ≤ 250 immunoassays per day. Conclusions: A multisite, international analyzer familiarization study is a practical means of confirming that a new instrument meets both a manufacturer's design specifications and users' real world expectations and provides a pragmatic test for the system. The experience of investigators at seven sites around the world indicates that a new fully automated chemiluminescent system is suitable for use.",
keywords = "Chemiluminescent immunoassay, Immunoassay, Immunoassay analyzer, Instrument evaluation",
author = "{De Keijzer}, {M. H.} and S. Perkins and V. Motta and D. Morelli and Cristol, {J. P.} and Dupuy, {A. M.} and Y. Hong and S. Watanabe and C. Waerdt and Grunewald, {R. W.}",
year = "2009",
language = "English",
volume = "55",
pages = "363--370",
journal = "Clinical Laboratory",
issn = "1433-6510",
publisher = "Verlag Klinisches Labor GmbH",
number = "9-10",

}

TY - JOUR

T1 - Multi-site, multi-country evaluation of analytical and operational performance of a low-mid volume chemiluminescent immunoassay analyzer

AU - De Keijzer, M. H.

AU - Perkins, S.

AU - Motta, V.

AU - Morelli, D.

AU - Cristol, J. P.

AU - Dupuy, A. M.

AU - Hong, Y.

AU - Watanabe, S.

AU - Waerdt, C.

AU - Grunewald, R. W.

PY - 2009

Y1 - 2009

N2 - Background: A new automated immunoassay low-mid volume (≤ 250 immunoassays/day) chemiluminescent analyzer, Abbott Architect i1000 SR, was evaluated by seven laboratories around the world (4 in Europe, one each in Canada, Japan, and the U.S.A.) to demonstrate equivalent performance for key operating characteristics (e.g., precision, turn around time, limit of detection, functional sensitivity, and linearity). Methods: The laboratories followed standard protocols to assess precision, limit of detection (LoD), functional sensitivity, assay linearity, method comparison, and sample carryover. Turn around time for three stat assays (B-hCG, BNP, and CK-MB) and the time required to complete workloads of 50 and 100 tests with a mixture of 75% routine tests and 25% stat tests was also evaluated. Results: Total precision was typically <5% CV for nine immunoassays. Analytical performance met design goals and demonstrated equivalency to package insert data for assays on market and in use for an existing high volume immunoassay system. Stat turn around times were consistent with the fixed analytical time of 15.6 minutes and met the expectations of the laboratories. Measured test throughput ranged from 47 - 54 tests per hour and demonstrated that the analyzer was fit for the intended purpose of supporting a laboratory that performs ≤ 250 immunoassays per day. Conclusions: A multisite, international analyzer familiarization study is a practical means of confirming that a new instrument meets both a manufacturer's design specifications and users' real world expectations and provides a pragmatic test for the system. The experience of investigators at seven sites around the world indicates that a new fully automated chemiluminescent system is suitable for use.

AB - Background: A new automated immunoassay low-mid volume (≤ 250 immunoassays/day) chemiluminescent analyzer, Abbott Architect i1000 SR, was evaluated by seven laboratories around the world (4 in Europe, one each in Canada, Japan, and the U.S.A.) to demonstrate equivalent performance for key operating characteristics (e.g., precision, turn around time, limit of detection, functional sensitivity, and linearity). Methods: The laboratories followed standard protocols to assess precision, limit of detection (LoD), functional sensitivity, assay linearity, method comparison, and sample carryover. Turn around time for three stat assays (B-hCG, BNP, and CK-MB) and the time required to complete workloads of 50 and 100 tests with a mixture of 75% routine tests and 25% stat tests was also evaluated. Results: Total precision was typically <5% CV for nine immunoassays. Analytical performance met design goals and demonstrated equivalency to package insert data for assays on market and in use for an existing high volume immunoassay system. Stat turn around times were consistent with the fixed analytical time of 15.6 minutes and met the expectations of the laboratories. Measured test throughput ranged from 47 - 54 tests per hour and demonstrated that the analyzer was fit for the intended purpose of supporting a laboratory that performs ≤ 250 immunoassays per day. Conclusions: A multisite, international analyzer familiarization study is a practical means of confirming that a new instrument meets both a manufacturer's design specifications and users' real world expectations and provides a pragmatic test for the system. The experience of investigators at seven sites around the world indicates that a new fully automated chemiluminescent system is suitable for use.

KW - Chemiluminescent immunoassay

KW - Immunoassay

KW - Immunoassay analyzer

KW - Instrument evaluation

UR - http://www.scopus.com/inward/record.url?scp=75749132812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749132812&partnerID=8YFLogxK

M3 - Article

VL - 55

SP - 363

EP - 370

JO - Clinical Laboratory

JF - Clinical Laboratory

SN - 1433-6510

IS - 9-10

ER -